" Korean versions of Wegovy and Mounjaro are coming"... Hanmi Science Surges More Than 10% in After-Hours Trading
Hanmi Pharmaceutical's GLP-1 Obesity Drug Receives Product Approval
Hanmi Science, the holding company of the Hanmi Pharmaceutical Group, is surging more than 10% in after-hours trading on Oct. 7.
As of 6:10 p.m. on Oct. 7, Hanmi Science was trading at 64,000 won, up 10.15% from its regular-session closing price of 58,100 won.
Hanmi Science is the operating holding company of the Hanmi Pharmaceutical Group, whose affiliates include Hanmi Pharmaceutical, Online Pharm, and JVM, a company specializing in automated pharmaceutical dispensing systems. Its main sources of revenue include managing affiliates, income from equity stakes, and patent and brand royalties. It also operates healthcare and pharmaceutical distribution businesses.
Hot Picks Today
A 12-Year-Old Girl Went to the Hospital After Her Blood Pressure Hit 225 and Was Stunned: "What Is This Coral Reef-Like Thing in Her Aorta?"
- "Samsung Electronics Employees Commute by Shuttle Bus"... More Than 5,000 Homes to Be Supplied in Seoul and Busan [Real Estate A to Z]
- “3.3 Million Won, Yet It Cracked with a ‘Snap’ When Unfolded”... Humiliation for iPhone Duo Amid Launch-Day Rush, Outclassed by Galaxy Fold?
- “I Thought Surely They Wouldn’t, but Grown Adults Did This”... Wedding Shoot Atop Tomb Sparks Controversy
- "If This Airs, I'm Dead"... Why a Restaurant Refused to Let Jeon Hyunmoo's Show Film
The stock is believed to be gaining after news broke that Epeoto Injector, a new GLP-1 obesity treatment developed in-house by Hanmi Pharmaceutical, received product approval from the Ministry of Food and Drug Safety. Hanmi Pharmaceutical is preparing to launch the drug with the goal of supplying it in South Korea by the end of the year.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
